- Home
- NEWT vs AMRN Comparison
NEWT vs AMRN Comparison
Compare NEWT & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$16.37
Company Overview
Basic Information| Metric | NEWT | AMRN |
|---|---|---|
| Founded | 1998 | 1989 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 395.5M | 339.8M |
| IPO Year | N/A | 1998 |
Fundamental Metrics
Financial Performance| Metric | NEWT | AMRN |
|---|---|---|
| Price | $11.73 | $16.37 |
| Analyst Decision | Hold | Strong Sell |
| Analyst Count | 3 | 1 |
| Target Price | ★ $14.00 | $12.00 |
| AVG Volume (30 Days) | ★ 162.5K | 86.0K |
| Earning Date | 01-01-0001 | 05-19-2026 |
| Dividend Yield | ★ 6.34% | N/A |
| EPS Growth | N/A | ★ 55.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $181,104,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.45 | N/A |
| P/E Ratio | $5.99 | ★ N/A |
| Revenue Growth | N/A | ★ 39.22 |
| 52 Week Low | $9.12 | $0.39 |
| 52 Week High | $14.91 | $20.90 |
Technical Indicators
Market Signals| Indicator | NEWT | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 35.60 | 66.00 |
| Support Level | $11.72 | $14.65 |
| Resistance Level | $12.41 | $16.94 |
| Average True Range (ATR) | 0.47 | 0.78 |
| MACD | -0.08 | 0.23 |
| Stochastic Oscillator | 15.17 | 92.84 |
Price Performance
Historical Comparison NEWT
AMRN
About NEWT NewtekOne Inc.
NewtekOne Inc is a financial holding company engaged in providing financial solutions to its Client Base. It is an internally managed non-diversified closed-end management investment company. It has four reportable segments Banking, Alternative Lending, Technology, NSBF, and Payments.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.